ReviewNature reviews. Disease primers2026
Tourette syndrome.
Review in Nature reviews. Disease primers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tourette syndrome is characterized by the presence of motor and phonic tics. Individuals with Tourette syndrome can have a spectrum of related behaviours including attention deficit hyperactivity features, obsessions, compulsions, impulsions and complex tics. The pathophysiology of Tourette syndrome is thought to reflect genetic influences on the development and function of cortical-striatal-thalamic-cortical and broader cortical-subcortical circuitry implicated in motor and inhibitory control and interoceptive processing, which may contribute to the characteristic 'urge-tic-relief' cycles. Shared genetic risks resulting in pleiotropy and overlapping neurocircuitry could explain some of the psychiatric comorbidities of Tourette syndrome. Management typically includes education, psychosocial support and behavioural therapy alongside pharmacotherapy for those with more severe tics or those unresponsive to behavioural therapy. Deep brain stimulation is used in severe, incapacitating and treatment-refractory cases persisting into adult life. Approaches aimed at improving quality of life and management of psychiatric comorbidities are also critically important. Future research should include considering refining the diagnostic criteria and delineating functional tic disorders, as well as the tic-related obsessive-compulsive behaviours, as this may have implications for treatment, understanding the underlying neurobiology, and the development of personalized interventions focusing on core tic-related features, psychiatric comorbidities and improving quality of life.
Indexed as
Identifiers
42850293What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.